Antibiotic Resistance Market Size Estimation, Growth Insights, Share Analysis, COVID-19 Impact and Industry Overview By 2025
Research Reports
Dec 29, 2020
Global Antibiotic Resistance Market Size, Growth and Trends Analysis by Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies), Disease (Complicated Urinary Tract Infection (cUTI), Blood Stream Infections (BDS), Complicated Intra-Abdominal Infections (cIAI), Clostridium Difficile Infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Community-Acquired Bacterial Pneumonia (CABP), Others), Pathogen (Staphylococcus Aureus , Streptococcus pneumonia, Acinetobacter, Enterococcus Faecium, Hemophilus Influenzae, Pseudomonas Aeruginosa, Clostridium Difficile, K. Pneumoniae, Others), End-User and Region, Forecast till 2025
Antibiotic Resistance Market Regional Insight
The antibiotic resistance market has been regionally dissected into Europe, APAC/Asia Pacific, MEA/Middle East & Africa and the Americas.
The Americas is advancing rapidly and can gain the top position in the global antibiotic resistance market, as a result of the extensive growth of the pharmaceutical industry. Continuous drug launches and the sound financial condition of the region supplement the market growth as well. The US remains the top revenue contributor, thanks to the prevalence of strict guidelines like IDSA that pertain to the treatment of CDI. These help promote the use of novel therapies, and ultimately benefit the regional market to a large extent.
Request Free Sample Copy of the report “ Global Antibiotic Resistance Market Research Report, Forecast till 2025″ at: https://www.marketresearchfuture.com/sample_request/8579
The fast progression of the healthcare sector and the increasing expenditure in this regard has led the antibiotic resistance market in APAC to greater heights in recent years. APAC is presumed to be the fastest-advancing market and the front liners are expected to be Japan, India, China, Australia and South Korea. The region is home to close to two-thirds of the global population and is a hot-spot for antimicrobial resistance. Rapid urbanization has led to an environment where hygiene is questionable, wastewater management is substandard, and the rising air pollution has led to surge in respiratory conditions that are generally treated with antibiotics. These factors have given rise to the need for antibiotic resistance market in the region.
Antibiotic Resistance Market Renowned Firms
Some of the renowned firms profiled are Entasis Therapeutics (US), Procarta Biosystems (England), PARATEK therapeutics (US), Seres Therapeutics (US), Nabriva Therapeutics plc (Ireland), Achaogen, Inc. (US), NEMESIS BIOSCIENCE LTD (UK), MELINTA THERAPEUTICS, INC. (US), Allecra Therapeutics (US), Tetraphase Pharmaceuticals (US), Basilea Pharmaceutica Ltd. (Switzerland), Theravance Biopharma (UK), to name a few.
Antibiotic Resistance Market Scope
The growing cases of antibiotic-resistant infections along with the fast emergence of various multi-drug resistant pathogens have resulted in signficant growth of the antibiotic resistance market. A number of biotech firms like Achaogen, Nabriva Therapeutics and Melinta Therapeutics are continuously taking up the challenge of coming up with therapies with regard to antibiotic resistance. The involvement of several international organizations also works in favor of the market. Funding agencies including BARDA are giving strong backing to the biotech companies in the form of funds to carry out the early stage phases of their novel therapies, in terms of antibiotic resistant infections. These factors are deemed to bolster the antibiotic resistance market growth in the years ahead.
The Antibiotic Resistance Market can cross a valuation of USD 13,146 Million by 2025, reveals Market Research Future (MRFR). The market is also presumed to proceed at a rate of 5.8% between 2019 and 2025 (review period). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the antibiotic resistance market post the coronavirus disease outbreak.
Rising cases of infectious and chronic diseases worldwide has contributed immensely to the market growth in recent years. To elaborate, over 17 million people are currently suffering from some kind of contagious diseases worldwide. Further, the antibiotic resistance market also benefits from the spike in clinical trials associated with antibiotic resistance and the growth in initiatives undertaken across the globe to curb drug-resistance.
However, the market growth rate can be deterred by the risk of lower return on investments. On the bright side, significant funding by international agencies and growing financial backing from several biotech firms are anticipated to boost revenue generation in the market over the next few years. Several firms are currently leading the antibiotic resistance market, and are basically involved in strategic collaborations and product launches to fortify their global positions.
For instance, in July 2020, Pfizer, Inc. pledged close to USD 100 million to the recently launched Antimicrobial Resistance Action Fund, to address the accelerated demand for new antibiotics owing to the sharp increase in antibiotic-resistant infections worldwide.
Antibiotic Resistance Market Segmental Analysis
The key segments as per which the Antibiotic Resistance Market has been considered include Drug Class, Disease, Pathogen, and End User.
The drug class-based segments include Combination therapies, oxazolidinones, cephalosporins, lipoglycopeptides, tetracyclines, and more. The combination therapies category can most likely attain the leading position, on account of the escalating use of these therapies with regard to gram-negative infections.
The antibiotic resistance market, depending on the disease, has been bifurcated into bloodstream infections, complicated urinary tract infections, clostridium difficile infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, hospital-acquired bacterial pneumonia/ventilator, acute bacterial and skin structure infections, and more. The major share in the market is expected to be secured by the complicated urinary tract infections segment, since these are quite common worldwide, with studies confirming that close to 1,045 patients are currently suffering from UTI.
The antibiotic resistance industry, pathogen-wise, comprises streptococcus pneumoniae, staphylococcus aureus, enterococcus, campylobacter, acinetobacter, pseudomonas aeruginosa, Hemophilus influenzae, K. pneumoniae, clostridium difficile, and others. K. pneumoniae can achieve the fastest growth due to the drastic surge in cases around the world.
Top end users in the market include research organizations, hospitals & clinics, and more. The hospitals & clinics category is projected to take the lead since most of the procedures and treatments take place in hospitals, leading to higher use of antibiotic resistance drugs. Therefore, the antibiotic resistance market is presently growing at a significant pace.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/antibiotic-resistance-market-8579
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English